Microvascular Dilatation After Endogenous Induced Hyperinsulinemia

Insulin-induced Microvascular Dilatation During a Physiological Stimulus - Studies in Hypertension and Obesity.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00742456

Enrollment

Registered

2008-08-27

Start date

2009-01-31

Completion date

2010-08-31

Last updated

2011-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Obesity

Keywords

Microcirculation, Insulin, Hypertension, Obesity

Brief summary

In this study we will examine if the insulin-induced microvascular effects will occur after a physiological stimulus (i.e. a oral glucose tolerance test). With that the physiological importance of the insulin-induced microvascular dilatation can be elucidated. In this study we hypothesize that oral glucose intake and consequently the endogenous induced hyperinsulinemia will lead to insulin-induced microvascular dilatation in healthy normotensive subjects. Furthermore, we suggest that the insulin-mediated microvascular dilatation, resulting from this physiological induced hyperinsulinemia, will be less in hypertensive and obese subjects compared to healthy controls.

Interventions

DIETARY_SUPPLEMENTGlucose solution

single oral intake of 250 ml glucose solution (75gr sugar in 250ml of water)

DIETARY_SUPPLEMENTPlacebo

single intake of placebo solution (250ml of sweet flavored water, no sugar added), orally

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

healthy normotensive subjects: 1. 18-60 years 2. Caucasian 3. Blood pressure \<140/90 mmHg obese normotensive subjects: 1. 18-60 years 2. Caucasian 3. Blood pressure \<140/90 mmHg 4. BMI 30-38kg/m2 hypertensive subjects: 1. 18-60 years 2. Caucasian 3. Untreated hypertension \>140/90mmHg.

Exclusion criteria

for healthy normotensive and hypertensive subjects: 1. Obesity (BMI\>27kg/m2) 2. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure) 3. Diabetes mellitus according to the criteria of the ADA 4. Smoking 5. Alcohol use \>4U/day 6. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs) 7. Pregnancy 8. Wearing contact lenses for normotensive obese subjects: 1. Cardiovascular disease (stroke, coronary artery disease, peripheral vascular disease, heart failure) 2. Impaired glucose tolerance or diabetes mellitus according to the criteria of the ADA 3. Smoking 4. Alcohol use \>4U/day 5. Use of medication (antihypertensive drugs, lipid lowering drugs, corticosteroids, NNSAIDs) 6. Pregnancy 7. Wearing contact lenses

Design outcomes

Primary

Measure	Time frame
Functional recruitment of capillaries in the skin.	January 2009 - January 2010

Secondary

Measure	Time frame
Perfused capillary density in the nailfold.	January 2009 - January 2010
Endothelium- (in)dependent vasodilatation of finger skin microcirculation	January 2009 - January 2010
Density of arterioles, capillaries and venules in the bulbar conjunctiva.	January 2009 - January 2010
Diameter of arterioles and venules in the bulbar conjunctiva.	January 2009 - January 2010
Insulin sensitivity (HOMA-IR)	January 2009 - January 2010

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026